Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2011

01.02.2011 | Original Article

Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine

verfasst von: Noriko Takeuchi, Emi Takenoshita, Fumino Kato, Tomoko Terajima, Makoto Ogawa, Satoshi Suzuki, Takayuki Fujii, Eriko Kobayashi, Tomoya Sakurada, Nobunori Satoh, Shiro Ueda

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The evaluation of the progression of renal insufficiency, or decline in glomerular filtration rate (GFR), has been approached more simply and precisely by converting measured serum creatinine value into the reciprocal of serum creatinine, estimated GFR, or other parameters. Doubling of serum creatinine (simple doubling) is conveniently used as a surrogate endpoint for progression of renal disease but is thought to be biased unfairly by the initial value of serum creatinine (ScrInt). We proposed the definite decline in the reciprocal of serum creatinine (2–4 doubling) as a surrogate endpoint, comparing simple doubling with this new endpoint to verify the effect of ScrInt on the endpoint.

Methods

For the purpose of comparison between endpoints, 194 patients in a historical cohort of chronic glomerulonephritis were investigated. Kaplan–Meier survival analysis was performed with the composite endpoint of need for dialysis and either simple doubling or 2–4 doubling. Then, the distribution of ScrInt was compared between total patients and patients developing each endpoint.

Results

The endpoint value of serum creatinine (ScrEnd) with 2–4 doubling was lower than that with simple doubling at ScrInt <2.00 mg/dl, and the difference of ScrEnd between simple doubling and 2–4 doubling was larger, as ScrInt became lower. In patients reaching simple doubling, ScrInt was higher than that of the total patients (1.66 vs. 1.07 mg/dl in median, respectively; p < 0.001). In patients reaching 2–4 doubling, there was no significant difference in ScrInt.

Conclusion

Patients with low serum creatinine concentration at baseline had a tendency of prolonged development into simple doubling. In contrast, with 2–4 doubling, there was no bias of ScrInt.
Literatur
1.
Zurück zum Zitat Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed
2.
Zurück zum Zitat Gretz NM. How to assess the rate of progression of chronic renal failure in children? Pediatr Nephrol. 1994;8:499–504.CrossRefPubMed Gretz NM. How to assess the rate of progression of chronic renal failure in children? Pediatr Nephrol. 1994;8:499–504.CrossRefPubMed
3.
Zurück zum Zitat Stevens LA, Greene T, Levey AS. Surrogate endpoints for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006;1:874–84.CrossRefPubMed Stevens LA, Greene T, Levey AS. Surrogate endpoints for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006;1:874–84.CrossRefPubMed
4.
Zurück zum Zitat Rossing P. Doubling of serum creatinine: is it sensitive and relevant? Nephrol Dial Transpl. 1998;13:244–6.CrossRef Rossing P. Doubling of serum creatinine: is it sensitive and relevant? Nephrol Dial Transpl. 1998;13:244–6.CrossRef
5.
Zurück zum Zitat Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
6.
Zurück zum Zitat Horio M, Orita Y. Comparison of Jaffé rate assay and enzymatic method for the measurement of creatinine clearance. Jpn J Nephrol. 1996;38:296–9. Horio M, Orita Y. Comparison of Jaffé rate assay and enzymatic method for the measurement of creatinine clearance. Jpn J Nephrol. 1996;38:296–9.
7.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
8.
Zurück zum Zitat Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.CrossRefPubMed Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.CrossRefPubMed
9.
Zurück zum Zitat The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.CrossRef The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.CrossRef
10.
Zurück zum Zitat Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–40.CrossRefPubMed Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–40.CrossRefPubMed
11.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed
12.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. The RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. The RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed
13.
Zurück zum Zitat Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18:1889–98.CrossRefPubMed Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18:1889–98.CrossRefPubMed
14.
Zurück zum Zitat Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–85.CrossRefPubMed Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–85.CrossRefPubMed
15.
Zurück zum Zitat Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.PubMed Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.PubMed
16.
Zurück zum Zitat Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33.CrossRefPubMed Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33.CrossRefPubMed
17.
Zurück zum Zitat Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830–8.CrossRefPubMed Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830–8.CrossRefPubMed
18.
Zurück zum Zitat Mitch WE, Walser M, Buffington GA, Lemann J. A simple method of estimating progression of chronic renal failure. Lancet. 1976;2:1326–8.CrossRefPubMed Mitch WE, Walser M, Buffington GA, Lemann J. A simple method of estimating progression of chronic renal failure. Lancet. 1976;2:1326–8.CrossRefPubMed
Metadaten
Titel
Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine
verfasst von
Noriko Takeuchi
Emi Takenoshita
Fumino Kato
Tomoko Terajima
Makoto Ogawa
Satoshi Suzuki
Takayuki Fujii
Eriko Kobayashi
Tomoya Sakurada
Nobunori Satoh
Shiro Ueda
Publikationsdatum
01.02.2011
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2011
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0365-1

Weitere Artikel der Ausgabe 1/2011

Clinical and Experimental Nephrology 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.